The Centers for Medicare & Medicaid Services today finalized additional provisions for the Medicare Advantage and Part D prescription drug programs beginning in 2022.

The rule permits a “preferred” specialty tier for Part D, which will provide a lower cost-sharing amount than the other specialty tier by allowing Part D plans more negotiating power with manufacturers.

The rule also codifies updates to Star Ratings for Part D plans and requires Part D plans to disclose pharmacy performance measures to CMS. Beginning in 2023, plans must provide a real-time benefit tool to help enrollees find the most cost-effective prescription drugs for their needs.

Related News Articles

Headline
Sens. Roger Marshall, R-Kan., Kyrsten Sinema, D-Ariz., and John Thune, R-S.D., today introduced a Senate companion to AHA-supported legislation (H.R. 3173…
Headline
The AHA yesterday urged the Centers for Medicare & Medicaid Services to revise and reissue recent proposed regulations streamlining prior…
Headline
The Centers for Medicare & Medicaid Services today released its star ratings for 2022 Medicare Advantage and prescription drug plans, which are available…
Headline
The Centers for Medicare & Medicaid Services yesterday released premium and cost-sharing information for Medicare Advantage and Part D prescription drug…
Headline
The Centers for Medicare & Medicaid Services today issued a Health Plan Management System memo to all Medicare Advantage Organizations and Medicare-…
Headline
The AHA today expressed support for the Improving Seniors’ Timely Access to Care Act of 2021 (H.R. 3173), bipartisan legislation that would establish…